{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:16:26Z","timestamp":1790702186420,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s11910-023-01264-4","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T08:23:43Z","timestamp":1680596623000},"page":"201-212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Growing Spectrum of Autoimmune Nodopathies"],"prefix":"10.1007","volume":"23","author":[{"given":"Pranjal","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igal","family":"Mirman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Shahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6865-9045","authenticated-orcid":false,"given":"Divyanshu","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"issue":"10","key":"1264_CR1","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1016\/j.clinph.2013.03.025","volume":"124","author":"A Uncini","year":"2013","unstructured":"Uncini A, Susuki K, Yuki N. Nodo-paranodopathy: beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies. Clin Neurophysiol. 2013;124(10):1928\u201334. https:\/\/doi.org\/10.1016\/j.clinph.2013.03.025.","journal-title":"Clin Neurophysiol"},{"issue":"3","key":"1264_CR2","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/ana.23794","volume":"73","author":"L Querol","year":"2013","unstructured":"Querol L, Nogales-Gadea G, Rojas-Garcia R, Martinez-Hernandez E, Diaz-Manera J, Su\u00e1rez-Calvet X, Navas M, Araque J, Gallardo E, Illa I. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol. 2013;73(3):370\u201380. https:\/\/doi.org\/10.1002\/ana.23794.","journal-title":"Ann Neurol"},{"issue":"23","key":"1264_CR3","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1212\/WNL.0b013e31827689ad","volume":"79","author":"JK Ng","year":"2012","unstructured":"Ng JK, Malotka J, Kawakami N, Derfuss T, Khademi M, Olsson T, Linington C, Odaka M, Tackenberg B, Pr\u00fcss H, et al. Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology. 2012;79(23):2241\u20138. https:\/\/doi.org\/10.1212\/WNL.0b013e31827689ad.","journal-title":"Neurology"},{"issue":"10","key":"1264_CR4","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1212\/wnl.0000000000000205","volume":"82","author":"L Querol","year":"2014","unstructured":"Querol L, Nogales-Gadea G, Rojas-Garcia R, Diaz-Manera J, Pardo J, Ortega-Moreno A, Sedano MJ, Gallardo E, Berciano J, Blesa R, et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology. 2014;82(10):879\u201386. https:\/\/doi.org\/10.1212\/wnl.0000000000000205.","journal-title":"Neurology"},{"issue":"6","key":"1264_CR5","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1172\/jci124694","volume":"129","author":"C Manso","year":"2019","unstructured":"Manso C, Querol L, Lleix\u00e0 C, Poncelet M, Mekaouche M, Vallat JM, Illa I, Devaux JJ. Anti-neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo. J Clin Invest. 2019;129(6):2222\u201336. https:\/\/doi.org\/10.1172\/jci124694. In this paper, authors demonstrated the pathogenic mechanisms of NF155 IgG4 antibodies. These antibodies bind to NF155 on the schwann cells and delpete its level resulting in paranodal dysfunction.","journal-title":"J Clin Invest"},{"issue":"Pt 6","key":"1264_CR6","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/brain\/aww062","volume":"139","author":"C Manso","year":"2016","unstructured":"Manso C, Querol L, Mekaouche M, Illa I, Devaux JJ. Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects. Brain. 2016;139(Pt 6):1700\u201312. https:\/\/doi.org\/10.1093\/brain\/aww062.","journal-title":"Brain"},{"key":"1264_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/nxi.0000000000000639","volume":"7","author":"A Cortese","year":"2020","unstructured":"Cortese A, Lombardi R, Briani C, Callegari I, Benedetti L, Manganelli F, Luigetti M, Ferrari S, Clerici AM, Marfia GA, et al. Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: clinical relevance of IgG isotype. Neurol Neuroimmunol Neuroinflamm. 2020;7:1. https:\/\/doi.org\/10.1212\/nxi.0000000000000639.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"1264_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/jns.12455","volume":"26","author":"PYK Van den Bergh","year":"2021","unstructured":"Van den Bergh PYK, van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, Allen JA, Attarian S, Blomkwist-Markens PH, Cornblath DR, Eftimov F, et al. European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision. J Peripher Nerv Syst. 2021;26(3):242\u201368. https:\/\/doi.org\/10.1111\/jns.12455. These are the recently developed guidelines for CIDP that recognized neuropathies secondary to antibodies to nodal-paranodal structure as a distinct entity and named them as autoimmune nodopathies","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"1264_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/jnr.23197","volume":"91","author":"ED Buttermore","year":"2013","unstructured":"Buttermore ED, Thaxton CL, Bhat MA. Organization and maintenance of molecular domains in myelinated axons. J Neurosci Res. 2013;91(5):603\u201322. https:\/\/doi.org\/10.1002\/jnr.23197.","journal-title":"J Neurosci Res"},{"issue":"3","key":"1264_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrneurol.2014.260","volume":"11","author":"P Stathopoulos","year":"2015","unstructured":"Stathopoulos P, Alexopoulos H, Dalakas MC. Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders. Nat Rev Neurol. 2015;11(3):143\u201356. https:\/\/doi.org\/10.1038\/nrneurol.2014.260.","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"1264_CR11","doi-asserted-by":"publisher","first-page":"5616","DOI":"10.1073\/pnas.090034797","volume":"97","author":"JH Caldwell","year":"2000","unstructured":"Caldwell JH, Schaller KL, Lasher RS, Peles E, Levinson SR. Sodium channel Na(v)1.6 is localized at nodes of ranvier, dendrites, and synapses. Proc Natl Acad Sci U S A. 2000;97(10):5616\u201320. https:\/\/doi.org\/10.1073\/pnas.090034797.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1264_CR12","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.semcdb.2010.09.010","volume":"22","author":"MN Rasband","year":"2011","unstructured":"Rasband MN. Composition, assembly, and maintenance of excitable membrane domains in myelinated axons. Semin Cell Dev Biol. 2011;22(2):178\u201384. https:\/\/doi.org\/10.1016\/j.semcdb.2010.09.010.","journal-title":"Semin Cell Dev Biol"},{"key":"1264_CR13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3389\/fncel.2013.00196","volume":"7","author":"C Faivre-Sarrailh","year":"2013","unstructured":"Faivre-Sarrailh C, Devaux JJ. Neuro-glial interactions at the nodes of Ranvier: implication in health and diseases. Front Cell Neurosci. 2013;7:196. https:\/\/doi.org\/10.3389\/fncel.2013.00196.","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"1264_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/s0960-9822(01)00680-7","volume":"12","author":"P Charles","year":"2002","unstructured":"Charles P, Tait S, Faivre-Sarrailh C, Barbin G, Gunn-Moore F, Denisenko-Nehrbass N, Guennoc AM, Girault JA, Brophy PJ, Lubetzki C. Neurofascin is a glial receptor for the paranodin\/Caspr-contactin axonal complex at the axoglial junction. Curr Biol. 2002;12(3):217\u201320. https:\/\/doi.org\/10.1016\/s0960-9822(01)00680-7.","journal-title":"Curr Biol"},{"issue":"15","key":"1264_CR15","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1002\/jnr.22013","volume":"87","author":"J Rosenbluth","year":"2009","unstructured":"Rosenbluth J. Multiple functions of the paranodal junction of myelinated nerve fibers. J Neurosci Res. 2009;87(15):3250\u20138. https:\/\/doi.org\/10.1002\/jnr.22013.","journal-title":"J Neurosci Res"},{"issue":"2","key":"1264_CR16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/s0896-6273(01)00294-x","volume":"30","author":"MA Bhat","year":"2001","unstructured":"Bhat MA, Rios JC, Lu Y, Garcia-Fresco GP, Ching W, St Martin M, Li J, Einheber S, Chesler M, Rosenbluth J, et al. Axon-glia interactions and the domain organization of myelinated axons requires neurexin IV\/Caspr\/paranodin. Neuron. 2001;30(2):369\u201383. https:\/\/doi.org\/10.1016\/s0896-6273(01)00294-x.","journal-title":"Neuron"},{"issue":"2","key":"1264_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/s0896-6273(01)00296-3","volume":"30","author":"ME Boyle","year":"2001","unstructured":"Boyle ME, Berglund EO, Murai KK, Weber L, Peles E, Ranscht B. Contactin orchestrates assembly of the septate-like junctions at the paranode in myelinated peripheral nerve. Neuron. 2001;30(2):385\u201397. https:\/\/doi.org\/10.1016\/s0896-6273(01)00296-3.","journal-title":"Neuron"},{"issue":"8","key":"1264_CR18","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/jnr.22015","volume":"87","author":"AM Pillai","year":"2009","unstructured":"Pillai AM, Thaxton C, Pribisko AL, Cheng JG, Dupree JL, Bhat MA. Spatiotemporal ablation of myelinating glia-specific neurofascin (Nfasc NF155) in mice reveals gradual loss of paranodal axoglial junctions and concomitant disorganization of axonal domains. J Neurosci Res. 2009;87(8):1773\u201393. https:\/\/doi.org\/10.1002\/jnr.22015.","journal-title":"J Neurosci Res"},{"issue":"6","key":"1264_CR19","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1136\/jnnp-2017-317192","volume":"89","author":"A Uncini","year":"2018","unstructured":"Uncini A, Vallat JM. Autoimmune nodo-paranodopathies of peripheral nerve: the concept is gaining ground. J Neurol Neurosurg Psychiatry. 2018;89(6):627\u201335. https:\/\/doi.org\/10.1136\/jnnp-2017-317192.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"1264_CR20","doi-asserted-by":"publisher","first-page":"7907","DOI":"10.1074\/jbc.M113.528489","volume":"289","author":"M Labasque","year":"2014","unstructured":"Labasque M, Hivert B, Nogales-Gadea G, Querol L, Illa I, Faivre-Sarrailh C. Specific contactin N-glycans are implicated in neurofascin binding and autoimmune targeting in peripheral neuropathies. J Biol Chem. 2014;289(11):7907\u201318. https:\/\/doi.org\/10.1074\/jbc.M113.528489.","journal-title":"J Biol Chem"},{"key":"1264_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/brain\/awac418","volume":"1","author":"L Appeltshauser","year":"2022","unstructured":"Appeltshauser L, Junghof H, Messinger J, Linke J, Haarmann A, Ayzenberg I, Baka P, Dorst J, Fisse AL, Gr\u00fcter T, et al. Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage. Brain. 2022;1:1. https:\/\/doi.org\/10.1093\/brain\/awac418. An original article that demonstrates binding characteristics and the pathogenic effects of anti-pan-neurofascin antibodies. The potenital role of complement in the pathogensis of pan NF antibody is also discussed.","journal-title":"Brain"},{"issue":"Pt 5","key":"1264_CR22","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1093\/brain\/awq372","volume":"134","author":"H Pr\u00fcss","year":"2011","unstructured":"Pr\u00fcss H, Schwab JM, Derst C, G\u00f6rtzen A, Veh RW. Neurofascin as target of autoantibodies in Guillain-Barre syndrome. Brain. 2011;134(Pt 5):e173\u2013e74. https:\/\/doi.org\/10.1093\/brain\/awq372.","journal-title":"Brain"},{"issue":"1","key":"1264_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1529-8027.2012.00372.x","volume":"17","author":"JJ Devaux","year":"2012","unstructured":"Devaux JJ, Odaka M, Yuki N. Nodal proteins are target antigens in Guillain-Barr\u00e9 syndrome. J Peripher Nerv Syst. 2012;17(1):62\u201371. https:\/\/doi.org\/10.1111\/j.1529-8027.2012.00372.x.","journal-title":"J Peripher Nerv Syst"},{"issue":"10","key":"1264_CR24","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1136\/jnnp-2021-326343","volume":"92","author":"J Fehmi","year":"2021","unstructured":"Fehmi J, Davies AJ, Walters J, Lavin T, Keh R, Rossor AM, Munteanu T, Delanty N, Roberts R, B\u00e4umer D, et al. IgG(1) pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality. J Neurol Neurosurg Psychiatry. 2021;92(10):1089\u201395. https:\/\/doi.org\/10.1136\/jnnp-2021-326343. A detailed account of clinical, immunological, electrophysiological and treatment is provided for pan NF antibody AN","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1264_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1212\/nxi.0000000000000603","volume":"6","author":"H Stengel","year":"2019","unstructured":"Stengel H, Vural A, Brunder AM, Heinius A, Appeltshauser L, Fiebig B, Giese F, Dresel C, Papagianni A, Birklein F, et al. Anti-pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathy. Neurol Neuroimmunol Neuroinflamm. 2019;6:5. https:\/\/doi.org\/10.1212\/nxi.0000000000000603.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"1264_CR26","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1212\/wnl.0000000000004773","volume":"90","author":"E Burnor","year":"2018","unstructured":"Burnor E, Yang L, Zhou H, Patterson KR, Quinn C, Reilly MM, Rossor AM, Scherer SS, Lancaster E. Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies. Neurology. 2018;90(1):e31\u20138. https:\/\/doi.org\/10.1212\/wnl.0000000000004773.","journal-title":"Neurology"},{"issue":"6","key":"1264_CR27","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1007\/s10072-021-05811-0","volume":"43","author":"G Liberatore","year":"2022","unstructured":"Liberatore G, De Lorenzo A, Giannotta C, Manganelli F, Filosto M, Cosentino G, Cocito D, Briani C, Cortese A, Fazio R, et al. Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database. Neurol Sci. 2022;43(6):3939\u201347. https:\/\/doi.org\/10.1007\/s10072-021-05811-0.","journal-title":"Neurol Sci"},{"issue":"12","key":"1264_CR28","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1007\/s00415-020-10041-z","volume":"267","author":"E Delmont","year":"2020","unstructured":"Delmont E, Brodovitch A, Kouton L, Allou T, Beltran S, Brisset M, Camdessanch\u00e9 JP, Cauquil C, Cirion J, Dubard T, et al. Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera. J Neurol. 2020;267(12):3664\u201372. https:\/\/doi.org\/10.1007\/s00415-020-10041-z.","journal-title":"J Neurol"},{"key":"1264_CR29","doi-asserted-by":"publisher","first-page":"577074","DOI":"10.1016\/j.jneuroim.2019.577074","volume":"337","author":"X Zhang","year":"2019","unstructured":"Zhang X, Zheng P, Devaux JJ, Wang Y, Liu C, Li J, Guo S, Song Y, Wang Q, Feng X, et al. Chronic inflammatory demyelinating polyneuropathy with anti-NF155 IgG4 in China. J Neuroimmunol. 2019;337:577074. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.577074.","journal-title":"J Neuroimmunol"},{"issue":"10","key":"1264_CR30","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/acn3.248","volume":"2","author":"H Ogata","year":"2015","unstructured":"Ogata H, Yamasaki R, Hiwatashi A, Oka N, Kawamura N, Matsuse D, Kuwahara M, Suzuki H, Kusunoki S, Fujimoto Y, et al. Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol. 2015;2(10):960\u201371. https:\/\/doi.org\/10.1002\/acn3.248.","journal-title":"Ann Clin Transl Neurol"},{"key":"1264_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/nxi.0000000000001098","volume":"9","author":"L Mart\u00edn-Aguilar","year":"2022","unstructured":"Mart\u00edn-Aguilar L, Lleix\u00e0 C, Pascual-Go\u00f1i E, Caballero-\u00c1vila M, Mart\u00ednez-Mart\u00ednez L, D\u00edaz-Manera J, Rojas-Garc\u00eda R, Cort\u00e9s-Vicente E, Turon-Sans J, de Luna N, et al. Clinical and laboratory features in anti-NF155 autoimmune nodopathy. Neurol Neuroimmunol Neuroinflamm. 2022;9:1. https:\/\/doi.org\/10.1212\/nxi.0000000000001098. This is the largest cohort of NF155 antibody associated AN that describes the clinical features and treatment outcomes. It also discusses the utility of serum neurofilament level and antibody titers in disease monitoring","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1264_CR32","doi-asserted-by":"publisher","first-page":"577139","DOI":"10.1016\/j.jneuroim.2019.577139","volume":"339","author":"H Ogata","year":"2020","unstructured":"Ogata H, Isobe N, Zhang X, Yamasaki R, Fujii T, Machida A, Morimoto N, Kaida K, Masuda T, Ando Y, et al. Unique HLA haplotype associations in IgG4 anti-neurofascin 155 antibody-positive chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 2020;339:577139. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.577139.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"1264_CR33","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12974-017-0996-1","volume":"14","author":"L Martinez-Martinez","year":"2017","unstructured":"Martinez-Martinez L, Lleix\u00e0 MC, Boera-Carnicero G, Cortese A, Devaux J, Siles A, Rajabally Y, Martinez-Pi\u00f1eiro A, Carvajal A, Pardo J, et al. Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15. J Neuroinflammation. 2017;14(1):224. https:\/\/doi.org\/10.1186\/s12974-017-0996-1.","journal-title":"J Neuroinflammation"},{"key":"1264_CR34","doi-asserted-by":"publisher","first-page":"665136","DOI":"10.3389\/fneur.2021.665136","volume":"12","author":"JI Kira","year":"2021","unstructured":"Kira JI. Anti-neurofascin 155 antibody-positive chronic inflammatory demyelinating polyneuropathy\/combined central and peripheral demyelination: strategies for diagnosis and treatment based on the disease mechanism. Front Neurol. 2021;12:665136. https:\/\/doi.org\/10.3389\/fneur.2021.665136.","journal-title":"Front Neurol"},{"key":"1264_CR35","doi-asserted-by":"publisher","first-page":"637336","DOI":"10.3389\/fnins.2021.637336","volume":"15","author":"X Guo","year":"2021","unstructured":"Guo X, Tang L, Huang Q. Tang X: A systematic review and meta-analysis of autoantibodies for diagnosis and prognosis in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Front Neurosci. 2021;15:637336. https:\/\/doi.org\/10.3389\/fnins.2021.637336.","journal-title":"Front Neurosci"},{"key":"1264_CR36","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jneuroim.2019.01.017","volume":"330","author":"C Briani","year":"2019","unstructured":"Briani C, Salvalaggio A, Ruiz M, Cacciavillani M, Rinaldi F, Callegari I, Gasparotti R, Franciotta D. Tongue tremor in neurofascin-155 IgG4 seropositive chronic inflammatory polyradiculoneuropathy. J Neuroimmunol. 2019;330:178\u201380. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.01.017.","journal-title":"J Neuroimmunol"},{"issue":"4","key":"1264_CR37","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/acn3.539","volume":"5","author":"C Painous","year":"2018","unstructured":"Painous C, L\u00f3pez-P\u00e9rez M, Illa I, Querol L. Head and voice tremor improving with immunotherapy in an anti-NF155 positive CIDP patient. Ann Clin Transl Neurol. 2018;5(4):499\u2013501. https:\/\/doi.org\/10.1002\/acn3.539.","journal-title":"Ann Clin Transl Neurol"},{"issue":"24","key":"1264_CR38","doi-asserted-by":"publisher","first-page":"e2392","DOI":"10.1212\/wnl.0000000000012932","volume":"97","author":"S Shelly","year":"2021","unstructured":"Shelly S, Klein CJ, PJB D, Paul P, Mauermann ML, Berini SE, Howe B, Fryer JP, Basal E, Bakri HM, et al. Neurofascin-155 immunoglobulin subtypes: clinicopathologic associations and neurologic outcomes. Neurology. 2021;97(24):e2392\u2013e403. https:\/\/doi.org\/10.1212\/wnl.0000000000012932. In this paper, authors report clinical, electrodiagnostic and pathological features and long term outcomes of NF155 IgG4 mediated AN in comparision to NF155 IgG (NF155 IgG4 negative), NF155 IgGM and anti CNTN1 antibody and anti MAG neuropathy.","journal-title":"Neurology"},{"issue":"9","key":"1264_CR39","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1212\/wnl.0000000000002418","volume":"86","author":"JJ Devaux","year":"2016","unstructured":"Devaux JJ, Miura Y, Fukami Y, Inoue T, Manso C, Belghazi M, Sekiguchi K, Kokubun N, Ichikawa H, Wong AH, et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology. 2016;86(9):800\u20137. https:\/\/doi.org\/10.1212\/wnl.0000000000002418.","journal-title":"Neurology"},{"issue":"5","key":"1264_CR40","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/acn3.51550","volume":"9","author":"W Wang","year":"2022","unstructured":"Wang W, Liu C, Li W, Zhang D, Shan Y, Zheng J, Shan J, Zhao Y, Yan C, Wang Q. Clinical and diagnostic features of anti-neurofascin-155 antibody-positive neuropathy in Han Chinese. Ann Clin Transl Neurol. 2022;9(5):695\u2013706. https:\/\/doi.org\/10.1002\/acn3.51550.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"1264_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/jnnp-2014-309831","volume":"87","author":"H Ogata","year":"2016","unstructured":"Ogata H, Matsuse D, Yamasaki R, Kawamura N, Matsushita T, Yonekawa T, Hirotani M, Murai H, Kira J. A nationwide survey of combined central and peripheral demyelination in Japan. J Neurol Neurosurg Psychiatry. 2016;87(1):29\u201336. https:\/\/doi.org\/10.1136\/jnnp-2014-309831.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"1264_CR42","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/jnnp-2016-314895","volume":"88","author":"H Koike","year":"2017","unstructured":"Koike H, Kadoya M, Kaida KI, Ikeda S, Kawagashira Y, Iijima M, Kato D, Ogata H, Yamasaki R, Matsukawa N, et al. Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. J Neurol Neurosurg Psychiatry. 2017;88(6):465\u201373. https:\/\/doi.org\/10.1136\/jnnp-2016-314895.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"1264_CR43","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.nmd.2016.10.008","volume":"27","author":"JM Vallat","year":"2017","unstructured":"Vallat JM, Yuki N, Sekiguchi K, Kokubun N, Oka N, Mathis S, Magy L, Sherman DL, Brophy PJ, Devaux JJ. Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with anti-neurofascin 155 antibodies. Neuromuscul Disord. 2017;27(3):290\u20133. https:\/\/doi.org\/10.1016\/j.nmd.2016.10.008.","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"1264_CR44","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1093\/brain\/awx124","volume":"140","author":"E Delmont","year":"2017","unstructured":"Delmont E, Manso C, Querol L, Cortese A, Berardinelli A, Lozza A, Belghazi M, Malissart P, Labauge P, Taieb G, et al. Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. Brain. 2017;140(7):1851\u20138. https:\/\/doi.org\/10.1093\/brain\/awx124.","journal-title":"Brain"},{"issue":"7","key":"1264_CR45","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/brain\/awy134","volume":"141","author":"JM Vallat","year":"2018","unstructured":"Vallat JM, Mathis S, Magy L, Bounolleau P, Skarzynski M, Heitzmann A, Manso C, Devaux J, Uncini A. Subacute nodopathy with conduction blocks and anti-neurofascin 140\/186 antibodies: an ultrastructural study. Brain. 2018;141(7):e56. https:\/\/doi.org\/10.1093\/brain\/awy134.","journal-title":"Brain"},{"issue":"4","key":"1264_CR46","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.clinph.2020.01.013","volume":"131","author":"L Kouton","year":"2020","unstructured":"Kouton L, Boucraut J, Devaux J, Rajabally YA, Adams D, Antoine JC, Bourdain F, Brodovitch A, Camdessanch\u00e9 JP, Cauquil C, et al. Electrophysiological features of chronic inflammatory demyelinating polyradiculoneuropathy associated with IgG4 antibodies targeting neurofascin 155 or contactin 1 glycoproteins. Clin Neurophysiol. 2020;131(4):921\u20137. https:\/\/doi.org\/10.1016\/j.clinph.2020.01.013.","journal-title":"Clin Neurophysiol"},{"key":"1264_CR47","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1212\/nxi.0000000000000771","volume":"7","author":"D Dubey","year":"2020","unstructured":"Dubey D, Honorat JA, Shelly S, Klein CJ, Komorowski L, Mills JR, Brakopp S, Probst C, Lennon VA, Pittock SJ, et al. Contactin-1 autoimmunity: serologic, neurologic, and pathologic correlates. Neurol Neuroimmunol Neuroinflamm. 2020;7:4. https:\/\/doi.org\/10.1212\/nxi.0000000000000771.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"Pt 6","key":"1264_CR48","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1093\/brain\/awv054","volume":"138","author":"Y Miura","year":"2015","unstructured":"Miura Y, Devaux JJ, Fukami Y, Manso C, Belghazi M, Wong AH, Yuki N. Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain. 2015;138(Pt 6):1484\u201391. https:\/\/doi.org\/10.1093\/brain\/awv054.","journal-title":"Brain"},{"issue":"7","key":"1264_CR49","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/jnnp-2014-309916","volume":"86","author":"K Doppler","year":"2015","unstructured":"Doppler K, Appeltshauser L, Wilhelmi K, Villmann C, Dib-Hajj SD, Waxman SG, M\u00e4urer M, Weishaupt A, Sommer C. Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies. J Neurol Neurosurg Psychiatry. 2015;86(7):720\u20138. https:\/\/doi.org\/10.1136\/jnnp-2014-309916.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"1264_CR50","doi-asserted-by":"publisher","first-page":"E19","DOI":"10.1002\/mus.26392","volume":"59","author":"G Taieb","year":"2019","unstructured":"Taieb G, Le Quintrec M, Pialot A, Szwarc I, Perrochia H, Labauge P, Devaux JJ. \u201cNeuro-renal syndrome\u201d related to anti-contactin-1 antibodies. Muscle Nerve. 2019;59(3):E19\u2013e21. https:\/\/doi.org\/10.1002\/mus.26392.","journal-title":"Muscle Nerve"},{"issue":"4","key":"1264_CR51","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/brain\/awab014","volume":"144","author":"E Pascual-Go\u00f1i","year":"2021","unstructured":"Pascual-Go\u00f1i E, Fehmi J, Lleix\u00e0 C, Mart\u00edn-Aguilar L, Devaux J, H\u00f6ftberger R, Delmont E, Doppler K, Sommer C, Radunovic A, et al. Antibodies to the Caspr1\/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy. Brain. 2021;144(4):1183\u201396. https:\/\/doi.org\/10.1093\/brain\/awab014.","journal-title":"Brain"},{"issue":"12","key":"1264_CR52","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1093\/jnen\/nlw093","volume":"75","author":"JM Vallat","year":"2016","unstructured":"Vallat JM, Nizon M, Magee A, Isidor B, Magy L, P\u00e9r\u00e9on Y, Richard L, Ouvrier R, Cogn\u00e9 B, Devaux J, et al. Contactin-associated protein 1 (CNTNAP1) mutations induce characteristic lesions of the paranodal region. J Neuropathol Exp Neurol. 2016;75(12):1155\u20139. https:\/\/doi.org\/10.1093\/jnen\/nlw093.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"Pt 10","key":"1264_CR53","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1093\/brain\/aww189","volume":"139","author":"K Doppler","year":"2016","unstructured":"Doppler K, Appeltshauser L, Villmann C, Martin C, Peles E, Kr\u00e4mer HH, Haarmann A, Buttmann M, Sommer C. Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy. Brain. 2016;139(Pt 10):2617\u201330. https:\/\/doi.org\/10.1093\/brain\/aww189.","journal-title":"Brain"},{"key":"1264_CR54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1212\/nxi.0000000000000817","volume":"7","author":"L Appeltshauser","year":"2020","unstructured":"Appeltshauser L, Brunder AM, Heinius A, K\u00f6rtv\u00e9lyessy P, Wandinger KP, Junker R, Villmann C, Sommer C, Leypoldt F, Doppler K. Antiparanodal antibodies and IgG subclasses in acute autoimmune neuropathy. Neurol Neuroimmunol Neuroinflamm. 2020;7:5. https:\/\/doi.org\/10.1212\/nxi.0000000000000817. This study provides the evidence of switchting of immunoglobulin subclass from IgG3 in acute to IgG4 in chronic phase","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"1264_CR55","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.neuron.2005.10.019","volume":"48","author":"DL Sherman","year":"2005","unstructured":"Sherman DL, Tait S, Melrose S, Johnson R, Zonta B, Court FA, Macklin WB, Meek S, Smith AJ, Cottrell DF, et al. Neurofascins are required to establish axonal domains for saltatory conduction. Neuron. 2005;48(5):737\u201342. https:\/\/doi.org\/10.1016\/j.neuron.2005.10.019.","journal-title":"Neuron"},{"issue":"11","key":"1264_CR56","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/acn3.51220","volume":"7","author":"H Ogata","year":"2020","unstructured":"Ogata H, Zhang X, Inamizu S, Yamashita KI, Yamasaki R, Matsushita T, Isobe N, Hiwatashi A, Tobimatsu S, Kira JI. Optic, trigeminal, and facial neuropathy related to anti-neurofascin 155 antibody. Ann Clin Transl Neurol. 2020;7(11):2297\u2013309. https:\/\/doi.org\/10.1002\/acn3.51220.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"1264_CR57","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/BOR.0b013e3283412fd4","volume":"23","author":"A Nirula","year":"2011","unstructured":"Nirula A, Glaser SM, Kalled SL. Taylor FR: What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol. 2011;23(1):119\u201324. https:\/\/doi.org\/10.1097\/BOR.0b013e3283412fd4.","journal-title":"Curr Opin Rheumatol"},{"key":"1264_CR58","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3389\/fimmu.2018.00097","volume":"9","author":"I Koneczny","year":"2018","unstructured":"Koneczny I. A new classification system for IgG4 autoantibodies. Front Immunol. 2018;9:97. https:\/\/doi.org\/10.3389\/fimmu.2018.00097.","journal-title":"Front Immunol"},{"key":"1264_CR59","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1212\/nxi.0000000000200014","volume":"9","author":"A Jentzer","year":"2022","unstructured":"Jentzer A, Attal A, Rou\u00e9 C, Raymond J, Lleix\u00e0 C, Illa I, Querol L, Taieb G, Devaux J. IgG4 valency modulates the pathogenicity of anti-neurofascin-155 IgG4 in autoimmune nodopathy. Neurol Neuroimmunol Neuroinflamm. 2022;9:5. https:\/\/doi.org\/10.1212\/nxi.0000000000200014.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1264_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/nxi.0000000000001116","volume":"9","author":"MC Dalakas","year":"2022","unstructured":"Dalakas MC. IgG4-mediated neurologic autoimmunities: understanding the pathogenicity of IgG4, ineffectiveness of IVIg, and long-lasting benefits of anti-B cell therapies. Neurol Neuroimmunol Neuroinflamm. 2022;9:1. https:\/\/doi.org\/10.1212\/nxi.0000000000001116.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"1264_CR61","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","volume":"11","author":"JD L\u00fcnemann","year":"2015","unstructured":"L\u00fcnemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology--mode of action and clinical efficacy. Nat Rev Neurol. 2015;11(2):80\u20139. https:\/\/doi.org\/10.1038\/nrneurol.2014.253.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"1264_CR62","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12974-019-1462-z","volume":"16","author":"K Doppler","year":"2019","unstructured":"Doppler K, Schuster Y, Appeltshauser L, Biko L, Villmann C, Weishaupt A, Werner C, Sommer C. Anti-CNTN1 IgG3 induces acute conduction block and motor deficits in a passive transfer rat model. Journal of Neuroinflammation. 2019;16(1):73. https:\/\/doi.org\/10.1186\/s12974-019-1462-z.","journal-title":"Journal of Neuroinflammation"},{"issue":"10","key":"1264_CR63","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/wnl.0000000000004341","volume":"89","author":"MK Hehir","year":"2017","unstructured":"Hehir MK, Hobson-Webb LD, Benatar M, Barnett C, Silvestri NJ, Howard JF Jr, Howard D, Visser A, Crum BA, Nowak R, et al. Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review. Neurology. 2017;89(10):1069\u201377. https:\/\/doi.org\/10.1212\/wnl.0000000000004341.","journal-title":"Neurology"},{"issue":"6","key":"1264_CR64","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","volume":"74","author":"MN Carruthers","year":"2015","unstructured":"Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206605.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1264_CR65","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1212\/nxi.0000000000000149","volume":"2","author":"L Querol","year":"2015","unstructured":"Querol L, Rojas-Garc\u00eda R, Diaz-Manera J, Barcena J, Pardo J, Ortega-Moreno A, Sedano MJ, Ser\u00f3-Ballesteros L, Carvajal A, Ortiz N, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm. 2015;2(5):e149. https:\/\/doi.org\/10.1212\/nxi.0000000000000149.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1264_CR66","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3389\/fimmu.2020.00613","volume":"11","author":"M Marino","year":"2020","unstructured":"Marino M, Basile U, Spagni G, Napodano C, Iorio R, Gulli F, Todi L, Provenzano C, Bartoccioni E, Evoli A. Long-lasting rituximab-induced reduction of specific-but not total-IgG4 in MuSK-positive myasthenia gravis. Front Immunol. 2020;11:613. https:\/\/doi.org\/10.3389\/fimmu.2020.00613.","journal-title":"Front Immunol"},{"issue":"3","key":"1264_CR67","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","volume":"78","author":"J D\u00edaz-Manera","year":"2012","unstructured":"D\u00edaz-Manera J, Mart\u00ednez-Hern\u00e1ndez E, Querol L, Klooster R, Rojas-Garc\u00eda R, Su\u00e1rez-Calvet X, Mu\u00f1oz-Blanco JL, Mazia C, Straasheijm KR, Gallardo E, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology. 2012;78(3):189\u201393. https:\/\/doi.org\/10.1212\/WNL.0b013e3182407982.","journal-title":"Neurology"},{"issue":"10","key":"1264_CR68","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1007\/s00415-021-10537-2","volume":"268","author":"Y Fukami","year":"2021","unstructured":"Fukami Y, Iijima M, Koike H, Yamada S, Hashizume A, Katsuno M. Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients. J Neurol. 2021;268(10):3835\u201344. https:\/\/doi.org\/10.1007\/s00415-021-10537-2.","journal-title":"J Neurol"},{"key":"1264_CR69","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jneuroim.2016.07.009","volume":"298","author":"C Lebrun","year":"2016","unstructured":"Lebrun C, Bourg V, Bresch S, Cohen M, Rosenthal-Allieri MA, Desnuelle C, Ticchioni M. Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis. J Neuroimmunol. 2016;298:79\u201381. https:\/\/doi.org\/10.1016\/j.jneuroim.2016.07.009.","journal-title":"J Neuroimmunol"},{"key":"1264_CR70","doi-asserted-by":"publisher","first-page":"577280","DOI":"10.1016\/j.jneuroim.2020.577280","volume":"345","author":"L Jiao","year":"2020","unstructured":"Jiao L, Xiang Y, Li S, Zhang F, Ruan X, Guo S. Efficacy of low dose rituximab in treatment-resistant cidp with antibodies against nf-155. J Neuroimmunol. 2020;345:577280. https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577280.","journal-title":"J Neuroimmunol."},{"key":"1264_CR71","doi-asserted-by":"publisher","first-page":"939062","DOI":"10.3389\/fimmu.2022.939062","volume":"13","author":"Y Hou","year":"2022","unstructured":"Hou Y, Zhang C, Yu X, Wang W, Zhang D, Bai Y, et al. Effect of low-dose rituximab treatment on autoimmune nodopathy with anti-contactin 1 antibody. Front Immunol. 2022;13:939062. https:\/\/doi.org\/10.3389\/fimmu.2022.939062.","journal-title":"Front Immunol."},{"issue":"4","key":"1264_CR72","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/jns.12465","volume":"26","author":"M Fels","year":"2021","unstructured":"Fels M, Fisse AL, Schwake C, Motte J, Athanasopoulos D, Gr\u00fcter T, Spenner M, Breuer T, Starz K, Heinrich D, et al. Report of a fulminant anti-pan-neurofascin-associated neuropathy responsive to rituximab and bortezomib. J Peripher Nerv Syst. 2021;26(4):475\u201380. https:\/\/doi.org\/10.1111\/jns.12465.","journal-title":"J Peripher Nerv Syst"},{"issue":"6","key":"1264_CR73","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1111\/ene.15266","volume":"29","author":"F Scheibe","year":"2022","unstructured":"Scheibe F, Ostendorf L, Pr\u00fcss H, Radbruch H, Aschman T, Hoffmann S, Blau IW, Meisel C, Alexander T, Meisel A. Daratumumab for treatment-refractory antibody-mediated diseases in neurology. Eur J Neurol. 2022;29(6):1847\u201354. https:\/\/doi.org\/10.1111\/ene.15266.","journal-title":"Eur J Neurol"},{"issue":"3","key":"1264_CR74","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s13311-022-01210-1","volume":"19","author":"MC Dalakas","year":"2022","unstructured":"Dalakas MC. Autoimmune neurological disorders with IgG4 antibodies: a distinct disease spectrum with unique IgG4 functions responding to anti-B cell therapies. Neurotherapeutics. 2022;19(3):741\u201352. https:\/\/doi.org\/10.1007\/s13311-022-01210-1. Review article summarizing the immunological properties of IgG4 antibodies. Lack of response to IVIG, role of rituximab and potential newer therpies in IgG4 mediated neurological disorders are discussed.","journal-title":"Neurotherapeutics"},{"issue":"6","key":"1264_CR75","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/s1474-4422(18)30114-5","volume":"17","author":"S Misawa","year":"2018","unstructured":"Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, et al. Safety and efficacy of eculizumab in Guillain-Barr\u00e9 syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol. 2018;17(6):519\u201329. https:\/\/doi.org\/10.1016\/s1474-4422(18)30114-5.","journal-title":"Lancet Neurol"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-023-01264-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-023-01264-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-023-01264-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T02:13:02Z","timestamp":1683943982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-023-01264-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1264"],"URL":"https:\/\/doi.org\/10.1007\/s11910-023-01264-4","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]},"assertion":[{"value":"20 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}